Effect of Combination Therapy with Ledipasvir and Sofosbuvir (Hepasbuvir Plus) for Treatment of Patients with Hepatitis C Infectio
Phase 2
- Conditions
- Chronic hepatitis C infection.Chronic viral hepatitis C
- Registration Number
- IRCT2016050717413N15
- Lead Sponsor
- Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Med
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Inclusion Criteria: Iranian patients with genotype-1 hepatitis C virus infection; with minimum age of 18 year old; with or without previous history of treatment (Peg-Interferon, Ribavirin, Protease inhibitors including: Telaprevir and Boceprevir); Compensated or Decompensated Cirrhosis;
Exclusion Criteria
Co-infection with HIV infection; Patients with thalassemia; Patients with hemophilia; Patients with history of chronic hemodialysis; patients with history of liver transplantation
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hepatitis C Viral load. Timepoint: Before starting therapy, 4 weeks after starting therapy, end of therapy, 4 weeks after end of therapy, 12 weeks after end of therapy. Method of measurement: Quantitative viral load in laboratory.
- Secondary Outcome Measures
Name Time Method